Several clinical trials have demonstrated that the supplementation of Dipeptiven® in critically ill patients in Intensive Care Units (ICUs) is associated with better clinical outcomes, such as reduction of the infection rate, shortening of ICU and hospital lengths of stay (LOS), and a trend toward reduced mortality, when compared to standard TPN regimens.
Aim of the study is the pharmacoeconomic evaluation of Dipeptiven® vs. standard TPN in critically ill patients admitted to Italian ICUs. Historical data were actualized using official coefficients [14] .
No discounting on either costs or outcomes was needed, due to the short time horizon (hospitalization).
One-way and probabilistic sensitivity analyses (PSA -95% CI or SD= 20% of mean, if CI unavailable, were the tested ranges) were performed and the cost/effectiveness acceptability curve generated.
Two previous meta-analyses and their updates demonstrated the effectiveness of ala-glu in reducing mortality and emerging infections in critically ill ICU patients.
The Bayesian approach used to pool clinical trials results yielded estimates very close to other techniques. The advantage is that it integrates very well with the microsimulation technique, providing a whole distribution of effects.
Dipeptiven® treatment is expected to be more effective than standard TPN, as it would avoid about one third of deaths, one sixth of infections, and slightly reduce overall LOS.
Dipeptiven® treatment is expected to be averagely less expensive than standard TPN, with a mean cost saving of about € 300.
According to the model, ala-glu supplementation in Italian ICUs, besides improving patient outcomes, is very economically attractive: in 78% of simulation its use is expected to reduce overall costs.
In the remaining simulations, lifes and infections saved have to be traded off with some extra expense, which is in any case low and could be considered fully justified.
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In the base-case scenario, Dipeptiven® is expected to be more effective than standard TPN, as it would avoid almost one third (1,070 of 3,446) of deaths, about one sixth (316 of 1,880) of infections, and slightly reduce overall LOS.
Dipeptiven® is also expected to be averagely less expensive than standard TPN, with a mean cost saving of € 300, as treatment cost is offset by reduction in ICU and antibiotic costs.
Dipeptiven® is expected to averagely dominate standard TPN, as it results associated with better clinical and economic outcomes (Tab.V)
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Conclusions
In the PSA, mean effectiveness and cost estimates slightly differ from the ones resulting from base-case analysis, but the conclusions are consistent: Dipeptiven® is expected to be less expensive, and more effective, than standard TPN. Consequently, Dipeptiven® is expected to be more cost/effective than standard TPN, as the average cost per patient discharged alive is estimated as being about € 5,500 less than the corresponding figure for the standard therapy.
From the cost/effectiveness acceptability curve, it can be seen that Dipeptiven® has an estimated 78% probability of resulting dominant (probability of resulting cost/effective with a WTP of € 0), a 90% probability of resulting cost/effective if the decision maker is willing to pay up to € 1,500 to avoid one patient death, and of 100% if this willingness to pay is around € 5,500.
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Description Value
Probability of being transferred to ward from ICU 74.3%
Probability of being discharged from ICU directly to home 1.5%
Probability of dying in ICU 24.2%
Probability of dying in ward 13.9%
Tab.I -Transition probabilities, derived from the Margherita project report [1] Fig Willingness to pay (€/Death avoided) P rob ab ility co st/effective
